Patents by Inventor Yuedi WANG

Yuedi WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • General sequence of chimeric antigen receptor, chimeric antigen receptor and an application thereof
    Patent number: 11993662
    Abstract: The present invention provides a general sequence of chimeric antigen receptor (CAR) and an application thereof, The hinge domain in the general sequence includes hinge domain V-5, hinge domain V-4-5, hinge domain V-3-4-5, hinge domain V-2-3-4-5 or hinge domain V-1-2-3-4-5. The CAR constructed by using the general sequence of the chimeric antigen receptor of the present invention can significantly improve the antigen-specific immune response of CAR-T cells, enhance the sensitivity of CAR-T cells and resist exhaustion, so as to enhance the therapeutic effect of CAR-T cells and enhance the therapeutic effect of anti-tumor agents. At the same time, the CAR containing the general sequence of the present invention is suitable for transfection of immune cells such as T cells and NK cells, and can be broadly applied to tumor therapy.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: May 28, 2024
    Assignee: Fudan University
    Inventors: Yiwei Chu, Yuedi Wang, Feifei Luo
  • General Sequence Of Chimeric Antigen Receptor, Chimeric Antigen Receptor And An Application Thereof
    Publication number: 20210101995
    Abstract: The present invention provides a general sequence of chimeric antigen receptor (CAR) and an application thereof, The hinge domain in the general sequence includes hinge domain V-5, hinge domain V-4-5, hinge domain V-3-4-5, hinge domain V-2-3-4-5 or hinge domain V-1-2-3-4-5. The CAR constructed by using the general sequence of the chimeric antigen receptor of the present invention can significantly improve the antigen-specific immune response of CAR-T cells, enhance the sensitivity of CAR-T cells and resist exhaustion, so as to enhance the therapeutic effect of CAR-T cells and enhance the therapeutic effect of anti-tumor agents. At the same time, the CAR containing the general sequence of the present invention is suitable for transfection of immune cells such as T cells and NK cells, and can be broadly applied to tumor therapy.
    Type: Application
    Filed: September 22, 2020
    Publication date: April 8, 2021
    Inventors: Yiwei CHU, Yuedi WANG, Feifei LUO